51
Views
5
CrossRef citations to date
0
Altmetric
Review

H1 antihistamines: patent highlights 2000 – 2005

&
Pages 109-117 | Published online: 24 Jan 2006

Bibliography

  • AKDIS CA, BLASER K: Histamine in the immune regulation of allergic inflammation. J. Allergy Clin. Immunol. (2003) 112(1):15-22.
  • SCHNEIDER E, ROLLI-DERKINDEREN M, AROCK M et al.: Trends in histamine research: new functions during immune responses and hematopoiesis. Trends Immunol. (2002) 23(5):255-263.
  • MACGLASHAN D: Histamine: a mediator of inflammation. J. Allergy Clin. Immunol. (2003) 112(4):S53-S59.
  • BERGER WE: Overview of allergic rhinitis. Ann. Allergy Asthma Immunol. (2003) 90:7-12.
  • BOUSQUET J, ARIA WORKSHOP GROUP: Allergic rhinitis and its impact on asthma. J. Allergy Clin. Immunol. (2001) 108(5):S147-S334.
  • SIMONS FE: Advances in H1-antihistamines. N. Engl. J. Med. (2004) 351:2202-2217.
  • TOGIAS A: H1-receptors: localization and role in airway physiology and in immune functions. J. Allergy Clin. Immunol. (2003) 112(4):S60-S68.
  • SIMONS FE: H1-antihistamines: more relevant than ever in the treatment of allergic disorders. J. Allergy Clin. Immunol. (2003) 112(4):S42-S52.
  • LEURS R, SMIT MJ, TENSEN CP, TER LAAK AM, TIMMERMAN H: Site-directed mutagenesis of the histamine H1-receptor reveals the selective interaction of asparagine 207 with subclasses of H1 receptor agonists. Biochem. Biophys. Res. Commun. (1994) 201(1):295-301.
  • BAKKER RA, WIELAND K, TIMMERMAN H, LEURS R: Constitutive activity of the histamine H1 receptor reveals inverse agonism of histamine H1 receptor antagonists. Eur. J. Pharmacol. (2000) 387(1):R5-R7.
  • WALSH GM: The clinical relevance of the anti-inflammatory properties of antihistamines. Allergy (2000) 55(Suppl.60):53-61.
  • STAUB A, BOVET D: Actions de la thymoethyl-diethylamine (929F) et des éthers phénoliques sur le choc anaphylactique de cobaye. CR Soc. Biol. (1937) 128:818-825.
  • VAN-CAUWENBERGE P, BACHERT C, PASSALACQUA G et al.: Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy (2000) 55(2):116-134.
  • TIMMERMAN H: Factors involved in the absence of sedative effects by the second-generation antihistamines. Allergy (2000) 55(Suppl.60):5-10.
  • DUBUSKE LM: Second-generation antihistamines: the risk of ventricular arrhythmias. Clin Ther. (1999) 21(2):281-295.
  • SUESSBRICH H, WALDEGGER S, LANG F, BUSCH AE: Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole. FEBS Lett. (1996) 385(1-2):77-80.
  • RENWICK AG: The metabolism of antihistamines and drug interactions: the role of cytochrome P450 enzymes. Clin. Exp. Allergy (1999) 29(Suppl.3):116-124.
  • HOLGATE ST, CANONICA GW, SIMONS FEet al.: Consensus Group on New-Generation Antihistamines (CONGA): present status and recommendations. Clin. Exp. Allergy (2003) 33(9):1305-1324.
  • CHRISTOPHE B, CARLIER B, GILLRAD M, CHATELAIN P, PECK M, MASSINGHAM R: Histamine H1 receptor antagonism by Cetirizine in isolated guinea pig tissues: influence of receptor reserve and dissociation kinetics. Eur. J. Pharmacol. (2003) 470(1-2):87-94.
  • MCLEOD RL, MINGO GG, HEREZKU C et al.: Combined histamine H1 and H3 receptor blockade produces nasal decongestion in an experimental model of nasal congestion. Am. J. Rhinol. (1999) 13(5):391-399.
  • ARRANG JM, GARBARG M, SCHWARTZ JC: Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature (1983) 302(5911):832-837.
  • LEURS R, BLANDINA P, TEDFORD C, TIMMERMAN H: Therapeutic potential of histamine H3 receptor agonists and antagonists. Trends Pharmacol. Sci. 19(5):177-183 (1998).
  • MCLEOD RL, EGAN RW, CUSS FM, BOLSER DC, HEY JA: Histamine H3 antagonists. In: New Drugs for Asthma, Allergy and COPD. Hansel TT, Barnes PJ (Eds), Prog. Respir. Res., Karger, Basel, Switzerland (2001) 31:133-136.
  • STARK H: Recent advances in histamine H3/H4 receptor ligands. Expert Opin. Ther. Patents (2003) 13(6):851-865.
  • ELSNER J, ESCHER SE, FORSSMANN U: Chemokine receptor antagonists: a novel therapeutic approach in allergic diseases. Allergy (2004) 59(12):1243-1258.
  • ERIN EM, WILLIAMS TJ, BARNES PJ, HANSEL TT: Eotaxin receptor (CCR3) antagonism in asthma and allergic disease. Curr. Drug Targets Inflamm. Allerg. (2002) 1(2):201-214.
  • JUSTICE JP, BROCHERS MT, CROSBY JR et al.: Ablation of eosinophils leads to a reduction of allergen-induced pulmonary pathology. Am. J. Physiol. Lung Cell. Mol. Physiol. (2003) 284(1):L169-L178.

Patents

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.